Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioXcel Therapeutics (BTAI) Enterprise Value (2022 - 2025)

BioXcel Therapeutics (BTAI) has 4 years of Enterprise Value data on record, last reported at -$37.3 million in Q3 2025.

  • For Q3 2025, Enterprise Value rose 7.59% year-over-year to -$37.3 million; the TTM value through Sep 2025 reached -$37.3 million, up 7.59%, while the annual FY2024 figure was -$29.9 million, 54.23% up from the prior year.
  • Enterprise Value reached -$37.3 million in Q3 2025 per BTAI's latest filing, down from -$18.6 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$18.6 million in Q2 2025 and bottomed at -$233.5 million in Q2 2022.
  • Average Enterprise Value over 4 years is -$106.4 million, with a median of -$74.1 million recorded in 2024.
  • The widest YoY moves for Enterprise Value: up 66.99% in 2025, down 7.59% in 2025.
  • A 4-year view of Enterprise Value shows it stood at -$193.7 million in 2022, then soared by 66.33% to -$65.2 million in 2023, then skyrocketed by 54.23% to -$29.9 million in 2024, then fell by 25.01% to -$37.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Enterprise Value were -$37.3 million in Q3 2025, -$18.6 million in Q2 2025, and -$31.0 million in Q1 2025.